Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Confronting the pneumococcus: a target shift or bullet change?

S K Obaro1

  • 1Medical Research Council Laboratories, P.O. Box 273, Fajara, Gambia. sobaro@gamtel.gm

Vaccine
|January 4, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial.

Lancet (London, England)·2005
Same author

Immunogenicity and efficacy of childhood vaccines in HIV-1-infected children.

The Lancet. Infectious diseases·2004
Same author

Vaccines for children: policies, politics and poverty.

Vaccine·2003
Same author

The new pneumococcal vaccine.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2002
Same author

Protein conjugate vaccines--how much is enough?

Trends in microbiology·2001
Same author

Evaluation of Binax now Streptococcus pneumoniae urinary antigen test in children in a community with a high carriage rate of pneumococcus.

The Pediatric infectious disease journal·2001

Pneumococcal conjugate vaccines show promise against pneumococcal disease, but serotype replacement and the need for better immune correlates of protection remain challenges. Further research into species-common protein-based vaccines is crucial.

Area of Science:

  • Immunology
  • Vaccinology
  • Infectious Diseases

Background:

  • Pneumococcal disease remains a significant global health threat despite advances in vaccine technology.
  • Current pneumococcal conjugate vaccines demonstrate efficacy but face challenges like serotype replacement and incomplete understanding of protective immunity.

Purpose of the Study:

  • To review the current state of pneumococcal disease research and vaccine development.
  • To highlight the limitations of existing vaccines and identify areas for future research, including protein-based and non-serotype-specific vaccines.

Main Methods:

  • Literature review of biomedical research on pneumococcal disease and vaccine technology.
  • Analysis of the immunogenicity and protective capacity of pneumococcal proteins in animal models.

Related Experiment Videos

  • Discussion of epidemiological factors influencing vaccine effectiveness.

    • Main Results:

    • Capsular antibodies are protective, but opsonic activity and avidity are more critical than concentration.
    • Protein-based vaccines are under development, showing promise in animal models.
    • Serotype replacement by non-vaccine strains is a significant threat, especially in high-burden areas.

    Conclusions:

    • New generation pneumococcal vaccines, particularly non-serotype-specific candidates, are needed.
    • Defining immune correlates of protection is essential for evaluating novel vaccines.
    • Improved diagnostic methods are required to accurately assess the true burden of pneumococcal disease.